ClinicalTrials.gg
Not yet recruitingNCT06892730SAFE-COVERUpdated Mar 25, 2025

Safety and Efficacy of TEVAR Combined With Long Bare-metal Stents in the Intervention of ATBAD

An interventional study of Hybrid TEVAR combined with long bare-metal stent intervention in Aortic Dissection Type B, sponsored by Yan'an Affiliated Hospital of Kunming Medical University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-03-25.

Sponsored by Yan'an Affiliated Hospital of Kunming Medical University · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The primary objective of this study is to evaluate the safety and efficacy of the TEVAR combined with extended bare-metal stenting (distal landing zone ≥2 cm below renal arteries) in patients with acute complicated type B aortic dissection (ATBAD).

Additionally, to prevent postoperative true lumen hypoperfusion in residual thoracoabdominal aortic dissection (visceral zone, infrarenal aorta, and iliac arteries) and persistent ischemic manifestations in visceral and lower extremity arteries post-endovascular repair, extended bare-metal stents are deployed to maintain adequate distal true lumen patency. This strategy ensures perfusion to visceral branches and lower limbs while preparing for future complete endovascular aortic repair.

Read the detailed description

Stanford type B aortic dissection (TBAD) accounts for 25-40% of all aortic dissections, characterized by acute onset, rapid progression, and high mortality, representing a critical cardiovascular emergency. While thoracic endovascular aortic repair (TEVAR) remains the standard intervention for TBAD, its benefits on true lumen remodeling and false lumen thrombosis are primarily limited to the stent-graft covered segment. Distal to the stent-graft, persistent re-entry tears in thoracoabdominal arteries convert preoperative exit sites into new entry points. Although TEVAR improves true lumen perfusion distal to the stent-graft, remodeling efficacy remains suboptimal, particularly in cases with preoperative true lumen collapse where post-TEVAR true lumen dimensions remain critically compressed by large false lumen volumes. Currently deployed stent-grafts typically measure 15-20 cm in length. Conventional TEVAR requires ≥1.5 cm proximal healthy aortic segment as landing zone to prevent retrograde type A dissection (RTAD) and ensure stability. For patients with inadequate proximal landing zones (\<1.5 cm), advanced techniques including branched stent-grafts, fenestrations, and parallel grafting have enabled TEVAR implementation even with ≤0.5 cm landing zones, facilitated by evolving device technologies and operator expertise. The "TEVAR+bare-stent" hybrid approach theoretically enhances aortic remodeling through reduced radial force. However, standard TEVAR typically deploys single stent-grafts at the proximal descending aortic tear. Extended stent-graft coverage beyond celiac axis level risks visceral artery occlusion, making maintenance of distal organ and limb perfusion an enduring challenge. Moreover, residual distal thoracoabdominal dissection carries risks of false lumen aneurysmal degeneration and rupture, particularly >5 years post-TEVAR. Secondary interventions for chronic residual dissections are complicated by intimal calcification from prolonged false lumen hypertension, combined with chronic hypoxia and inflammation that compromise aortic wall integrity. Persistent false lumen expansion and rupture in residual thoracoabdominal dissection are observed in 23-35% of conventional TEVAR cases, particularly affecting young-to-middle-aged patients with suboptimal blood pressure control beyond 5-year follow-up. Technical challenges in secondary visceral branch reconstruction further compromise long-term quality of life. Therefore, post-endovascular true lumen remodeling in thoracoabdominal segments warrants particular attention, as aortic remodeling constitutes a crucial determinant of therapeutic success beyond procedural technique alone.

This study aims to validate the feasibility and safety of proximal stent-graft plus extended distal bare-metal stenting in thoracoabdominal aorta, compare its efficacy with conventional TEVAR, and characterize its impacts on aortic remodeling and subsequent visceral/distal arterial reconstruction. We anticipate this research will provide critical clinical evidence for managing residual thoracoabdominal dissection after acute TBAD repair.

Using imaging-based analysis and clinical follow-up, this study will compare: (1) conventional TEVAR vs. (2) hybrid proximal stent-graft + extended distal bare-stent strategies in terms of morphological remodeling, adverse events, and long-term outcomes. The findings may elucidate differential impacts on aortic reconstruction and visceral/iliac revascularization, offering evidence-based guidance for managing distal dissection in acute TBAD.

02

Conditions studied

  • Aortic Dissection Type B

Keywords

  • ATBAD
  • TEVAR
  • Extension
  • Long bare metal scaffolding devices
03

In context

Lead sponsor

Yan'an Affiliated Hospital of Kunming Medical University is the lead sponsor of 9 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≧18 years old, ≦80 years old;
  • Acute phase with a course of disease ≦14 days;
  • CTA confirmed diagnosis of active dissection type B in accordance with the Stanford classification in the ESC guidelines, and requiring TEVAR surgery;
  • For patients with acute non-type A and non-type B aortic dissection involving the left subclavian artery: current technologies (such as fenestration, single branch, chimney, etc.) can be used to solve the reconstruction of the left subclavian artery;
  • The distal end of the dissection exceeds the renal artery plane;
  • Signed (emergency waiver applicable), with primary intervention using CTAG devices. Adjunctive procedures may include LSA revascularization, percutaneous fenestration, aortic/peripheral stenting, surgical fenestration, or bypass grafting.
  • Medical record completeness >90% with mandatory CTA data;
  • Protocol compliance including follow-up adherence

Exclusion criteria

Exclusion Criteria:

  • Dissection termination above renal arteries;
  • Major aortic surgery within 30 days prior (except LSA revascularization);
  • Iliofemoral stenosis/angulation precluding endovascular access;
  • Non-diagnostic CTA image quality;
  • Indeterminate symptom onset time;
  • Traumatic TBAD, intramural hematoma, or penetrating aortic ulcer;
  • Complete thoracic aortic thrombosis pre-TEVAR;
  • Re-intervention within 12 months post-TEVAR for non-aortic indications;
  • Renal failure: Baseline serum creatinine >2.5 mg/dL (high-risk for contrast nephropathy);
  • Known device material ;
  • Systemic infection increasing endograft infection risk;
  • Evidence of aortic infection;
  • Connective tissue disorders (e.g., Marfan syndrome);
  • Bowel necrosis from visceral ischemia;
  • Participation in other device/drug trials within 1 year;
  • Moribund status: 5 with \<24h ;
  • shock (SBP \<90 mmHg);
  • Pregnancy or lactation;
  • Active substance abuse.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Carstor® 70-240mm, AnkuraTMⅡ60-200mm, WeFlow-TbranchTM and Fabulous® Device Surgical Implant

    Subjects with acute type B aortic dissection were treated with an endovascular procedure using the Carstor® 70-240mm, AnkuraTMⅡ60-200mm, WeFlow-TbranchTM 160-240mm Thoracic Aortic Endoprosthesis and the Fabulous® 45-150mm long big bare stent via femoral artery access. (Permanent implant)

    Device: Hybrid TEVAR combined with long bare-metal stent intervention

Interventions

  • DeviceHybrid TEVAR combined with long bare-metal stent intervention

    - Primary TEVAR: Primary TEVAR: Employ Carstor® 70-240mm, AnkuraTMⅡ60-200mm, WeFlow-TbranchTM 160-240mm endograft deployed with ≥2cm proximal landing zone coverage. Concurrent bare-stenting: Post-TEVAR femoral access deployment of Fabulous® (45-150mm) long bare-metal stent with: Proximal overlap ≥3cm with TEVAR graft. Distal extension 2-6cm below renal artery plane. Maximum distal limit: above iliac bifurcation. - Intraprocedural angiography with spinal reference mapping guides precise stent positioning relative to visceral arteries and infrarenal aorta.

06

What researchers measure

Primary outcomes

  1. 30-day all-cause mortality

    30-day all-cause mortality

    Time frame: 30 days post-intervention

  2. Ratio of increase in aortic true lumen (%)

    Ratio of increase in aortic true lumen(%) including three parameters: 1. Diameter measurement (unit: mm): The total aortic diameter was obtained based on the 2020 SVS/STS reporting standards, and then the specific values of the true lumen diameter and false lumen diameter were obtained as a percentage of the straight line between the two lumens. 2. Area measurement (unit: mm2): The aortic false lumen area = the true and false lumen area - the true lumen area on the same measurement plane. 3. The change ratio (%) of true lumen diameter (mm) and area (mm2): Definition: Postoperative true lumen diameter increase ratio: (postoperative - preoperative) / preoperative\*100% True lumen diameter increase ratio after follow-up: (current follow-up - last follow-up) / last follow-up\*100% Postoperative true lumen area increase ratio: (postoperative - preoperative) / preoperative\*100% True lumen area increase ratio after follow-up: (current follow-up - last follow-up) / last follow-up area\*100%

    Time frame: 1 month, 6 months, 12 months after surgery

Secondary outcomes

  1. Aortic rupture incidence

    Aortic rupture incidence

    Time frame: 1 month, 6 months, 12 months after surgery

  2. Device-related complications

    * endoleak, spinal ischemia, organ failure * Classification and incidence rates

    Time frame: 1 month, 6 months, 12 months after surgery

  3. False lumen thrombosis grading

    1. Complete: No contrast enhancement 2. Partial: Partial contrast flow with thrombus 3. Patent: Full contrast opacification

    Time frame: 1 month, 6 months, 12 months after surgery

07

Study locations

1 site
  • Yan'an Affiliated Hospital of Kunming Medical University
    Kunming, Yunnan 650051, China
    • Zheng Dr. Jia, Ph.D. · Contactjiazhenghappy@163.com · +8613669776843
    • Xunqiang Prof. Liu, M.D. · Principal investigator
    • Zheng Dr. Jia, Ph.D. · Sub investigator
    • Ruhong Prof. Li, M.D. · Sub investigator
    • Enshuai Dr. Zhu, M.S. · Sub investigator
    • Huanjun Prof. Chen, M.S. · Sub investigator
    • Ying Dr. Yanf · Sub investigator
    • Min Dr. Ji, M.S. · Sub investigator
    • Chunxin Dr. Yang, M.S. · Sub investigator
    • Jinhui Dr. Zhang, M.D. · Sub investigator
    • Lei Dr. Cong, M.S. · Sub investigator
    • Jiaqi Dr. Li, M.S. · Sub investigator
    • Yan Dr. Wei, M.S. · Sub investigator
    • Liqiong Dr. Zhang · Sub investigator
08

References and documents

Publications

  • Rong D, Ge Y, Liu J, Liu X, Guo W. Combined proximal descending aortic endografting plus distal bare metal stenting (PETTICOAT technique) versus conventional proximal descending aortic stent graft repair for complicated type B aortic dissections. Cochrane Database Syst Rev. 2019 Oct 30;2019(10):CD013149. doi: 10.1002/14651858.CD013149.pub2. PubMed 31684692 ↗
  • Fattori R, Montgomery D, Lovato L, Kische S, Di Eusanio M, Ince H, Eagle KA, Isselbacher EM, Nienaber CA. Survival after endovascular therapy in patients with type B aortic dissection: a report from the International Registry of Acute Aortic Dissection (IRAD). JACC Cardiovasc Interv. 2013 Aug;6(8):876-82. doi: 10.1016/j.jcin.2013.05.003. PubMed 23968705 ↗
  • Nienaber CA, Kische S, Zeller T, Rehders TC, Schneider H, Lorenzen B, Bunger C, Ince H. Provisional extension to induce complete attachment after stent-graft placement in type B aortic dissection: the PETTICOAT concept. J Endovasc Ther. 2006 Dec;13(6):738-46. doi: 10.1583/06-1923.1. PubMed 17154712 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2025; primary completion for Mar 2027, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2025
First posted
Mar 25, 2025
StartEst.
Mar 31, 2025
Primary completionEst.
Mar 31, 2027
CompletionEst.
Mar 31, 2027
Last update
Mar 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06892730
Lead sponsor
Yan'an Affiliated Hospital of Kunming Medical University
Responsible party
Sponsor
First posted
Mar 25, 2025
Start date
Mar 31, 2025 (estimated)
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Mar 25, 2025

Study contacts

Xunqiang Prof. Liu, M.D.
Contact
liuxunqiang1001@163.com
+8613888390126
Zheng Dr. Jia, Ph.D.
Contact
jiazhenghappy@163.com
+8613669776843
Xunqiang Prof. Liu, M.D.
principal investigator · Yan'an Affiliated Hospital of Kunming Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion